Precerix

Precirix is a clinical-stage biotechnology company headquartered in Brussels, Belgium, dedicated to developing novel precision radiopharmaceuticals for cancer treatment. The company leverages its proprietary single-domain antibody (sdAb) platform to create targeted therapies that deliver radioisotopes directly to tumor cells while minimizing exposure to healthy tissue. Its lead candidate, CAM-H2, is currently being evaluated in a Phase 1/2 clinical trial for the treatment of HER2-positive metastatic breast and gastric cancer, including patients with brain metastases. Precirix's approach combines the high specificity of nanobodies with the potent cell-killing power of alpha and beta-emitting radionuclides. The company was founded as a spin-off from the Vrije Universiteit Brussel and has secured significant backing from leading life science investors.